Evidence map›Paper›PMID 39592836›Full record

ArticleOncogene2025

CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.

Elisa Rodrigues Sousa, Simone de Brot, Eugenio Zoni, Soheila Zeinali, Andrea Brunello, Mario Scarpa, Marta De Menna, Federico La Manna, Allen Abey Alexander, Irena Klima and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elisa Rodrigues SousaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-2658-0985
Simone de BrotCOMPATH, Institute of Animal Pathology, University of Bern, Bern, Switzerland.
Eugenio ZoniUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Soheila ZeinaliOrgans-on-chip Technologies Laboratory, ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.
Andrea BrunelloUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Mario ScarpaDepartment for BioMedical Research, Translational Organoid Research, University of Bern, Bern, Switzerland.
Marta De MennaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Federico La MannaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Allen Abey AlexanderUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Irena KlimaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
David W FreemanHuntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, USA.
Brooke L GatesHuntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, USA.
Domenico A CristaldiCellDynamics Isrl, Bologna, Italy.
Olivier T GuenatOrgans-on-chip Technologies Laboratory, ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0003-1103-9712
Boudewijn P T KruithofDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Benjamin T SpikeHuntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, USA.ORCID http://orcid.org/0000-0002-0893-3302
Panagiotis ChouvardasUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Marianna Kruithof-de JulioUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland. marianna.kruithofdejulio@unibe.ch.ORCID http://orcid.org/0000-0002-6085-7706

Funding

U.S. Department of Defense (United States Department of Defense) W81XWH1910432
6 · The paper itself

Abstract

CRIPTO (or CR-1 or TDGF1) is a protein that plays an active role in tumor initiation and progression. We have confirmed that increased expression of CRIPTO is associated with clinical and prostate-specific antigen (PSA) progression in human prostate tissues. Our approach involved gaining insight into the role of CRIPTO signaling in castration-resistant Nkx3.1-expressing cells (CARNs), targets for oncogenic transformation in prostate cancer (PCa), by integrating the existing Cripto

Indexed as

Epidermal Growth FactorGPI-Linked ProteinsIntercellular Signaling Peptides and ProteinsNeoplasm ProteinsProstatic NeoplasmsAnimalsCell Line, TumorEGF Family of ProteinsGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMaleMiceOrganoidsSignal TransductionTranscription FactorsEGF Family of ProteinsEpidermal Growth FactorGPI-Linked ProteinsHomeodomain ProteinsIntercellular Signaling Peptides and ProteinsNeoplasm ProteinsTDGF1 protein, humanTranscription Factors

Identifiers

PMID39592836
PMCPMC11810784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.